傲農生物(603363.SH):擬使用不超4億元暫時閒置募資進行現金管理
格隆匯5月6日丨傲農生物(603363.SH)公佈,公司於2022年5月6日召開第三屆董事會第八次會議、第三屆監事會第六次會議,審議通過了《關於使用部分暫時閒置募集資金進行現金管理的議案》,同意公司在確保不影響募集資金投資項目正常進行和募集資金安全的前提下,使用合計不超過4億元的暫時閒置募集資金進行現金管理,其中宜豐傲農農業開發有限公司使用資金額度不超過3.6億元、永新縣傲農生物科技有限公司使用資金額度不超過4000萬元,使用期限為自董事會審議通過之日起不超過12個月。在上述期限及額度範圍內,資金可以滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.